198 related articles for article (PubMed ID: 11594292)
1. Current strategies for controlling postprandial hyperglycaemia.
Kunt T
Int J Clin Pract Suppl; 2001 Sep; (123):19-23. PubMed ID: 11594292
[TBL] [Abstract][Full Text] [Related]
2. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
Giugliano D; Ceriello A; Razzoli E; Esposito K
Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
[TBL] [Abstract][Full Text] [Related]
3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
4. Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control.
Christiansen JS; Liebl A; Davidson JA; Ligthelm RJ; Halimi S
Diabetes Obes Metab; 2010 Feb; 12(2):105-14. PubMed ID: 19895637
[TBL] [Abstract][Full Text] [Related]
5. Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes.
Yacoub T
Postgrad Med; 2017 Nov; 129(8):791-800. PubMed ID: 29032696
[TBL] [Abstract][Full Text] [Related]
6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
7. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
9. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives.
Bonora E
Int J Clin Pract Suppl; 2002 Jul; (129):5-11. PubMed ID: 12166607
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
Herz M; Sun B; Milicevic Z; Erickson P; Fövènyi J; Grzywa M; Pelikanova T
Clin Ther; 2002 Jan; 24(1):73-86. PubMed ID: 11833837
[TBL] [Abstract][Full Text] [Related]
11. Postprandial glucose regulation: new data and new implications.
Leiter LA; Ceriello A; Davidson JA; Hanefeld M; Monnier L; Owens DR; Tajima N; Tuomilehto J;
Clin Ther; 2005; 27 Suppl B():S42-56. PubMed ID: 16519037
[TBL] [Abstract][Full Text] [Related]
12. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
14. Drug therapy of postprandial hyperglycaemia.
Mooradian AD; Thurman JE
Drugs; 1999 Jan; 57(1):19-29. PubMed ID: 9951949
[TBL] [Abstract][Full Text] [Related]
15. Insulin during pregnancy, labour and delivery.
de Valk HW; Visser GH
Best Pract Res Clin Obstet Gynaecol; 2011 Feb; 25(1):65-76. PubMed ID: 21186142
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
17. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
[TBL] [Abstract][Full Text] [Related]
18. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
[TBL] [Abstract][Full Text] [Related]
19. [Insulin therapy].
Brunetti P
Minerva Endocrinol; 2001 Jun; 26(2):65-86. PubMed ID: 11479436
[TBL] [Abstract][Full Text] [Related]
20. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
